Compile Data Set for Download or QSAR
Report error Found 47 Enz. Inhib. hit(s) with all data for entry = 1953
TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM347674(3-Ethynyl-5-((4-((4-(3-(3-(2-methylbut-3-yn-2-yl)-...)
Affinity DataIC50: 16nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM347672(1-(4-((2-((3-Methoxy-5-(2-(2-(2-methoxyethoxy)etho...)
Affinity DataIC50: 16nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM347675(1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...)
Affinity DataIC50: 21nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM347667(1-(4-((2-((3-Methoxy-5-(2-morpholinoethoxy)phenyl)...)
Affinity DataIC50: 22nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256621(US9481648, Ref Cpd A | US9790209, Example 2)
Affinity DataIC50: 24nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Respivert

US Patent
LigandPNGBDBM347667(1-(4-((2-((3-Methoxy-5-(2-morpholinoethoxy)phenyl)...)
Affinity DataIC50: 31nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM347673(3-((4-((4-(3-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl...)
Affinity DataIC50: 37nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Respivert

US Patent
LigandPNGBDBM347674(3-Ethynyl-5-((4-((4-(3-(3-(2-methylbut-3-yn-2-yl)-...)
Affinity DataIC50: 40nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Respivert

US Patent
LigandPNGBDBM347669(1-(4-((2-((6-(2-(Dimethylamino)ethoxy)pyridin-2-yl...)
Affinity DataIC50: 46nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Respivert

US Patent
LigandPNGBDBM256621(US9481648, Ref Cpd A | US9790209, Example 2)
Affinity DataIC50: 50nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM347660(1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...)
Affinity DataIC50: 60nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Respivert

US Patent
LigandPNGBDBM347672(1-(4-((2-((3-Methoxy-5-(2-(2-(2-methoxyethoxy)etho...)
Affinity DataIC50: 61nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Respivert

US Patent
LigandPNGBDBM347674(3-Ethynyl-5-((4-((4-(3-(3-(2-methylbut-3-yn-2-yl)-...)
Affinity DataIC50: 67nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM347671(3-((4-((4-(3-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl...)
Affinity DataIC50: 74nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM347666(1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...)
Affinity DataIC50: 81nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Respivert

US Patent
LigandPNGBDBM347660(1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...)
Affinity DataIC50: 85nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Respivert

US Patent
LigandPNGBDBM347662(1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...)
Affinity DataIC50: 87nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Respivert

US Patent
LigandPNGBDBM347662(1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...)
Affinity DataIC50: 113nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Respivert

US Patent
LigandPNGBDBM347675(1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...)
Affinity DataIC50: 148nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Respivert

US Patent
LigandPNGBDBM347672(1-(4-((2-((3-Methoxy-5-(2-(2-(2-methoxyethoxy)etho...)
Affinity DataIC50: 152nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Respivert

US Patent
LigandPNGBDBM347671(3-((4-((4-(3-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl...)
Affinity DataIC50: 158nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Respivert

US Patent
LigandPNGBDBM347666(1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...)
Affinity DataIC50: 185nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Respivert

US Patent
LigandPNGBDBM347672(1-(4-((2-((3-Methoxy-5-(2-(2-(2-methoxyethoxy)etho...)
Affinity DataIC50: 202nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM347662(1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...)
Affinity DataIC50: 203nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Respivert

US Patent
LigandPNGBDBM347673(3-((4-((4-(3-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl...)
Affinity DataIC50: 203nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Respivert

US Patent
LigandPNGBDBM347671(3-((4-((4-(3-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl...)
Affinity DataIC50: 214nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Respivert

US Patent
LigandPNGBDBM347673(3-((4-((4-(3-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl...)
Affinity DataIC50: 222nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Respivert

US Patent
LigandPNGBDBM347665(1-(4-((2-((3-(2-(Dimethylamino)ethoxy)phenyl)amino...)
Affinity DataIC50: 243nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Respivert

US Patent
LigandPNGBDBM347666(1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...)
Affinity DataIC50: 271nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Respivert

US Patent
LigandPNGBDBM347673(3-((4-((4-(3-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl...)
Affinity DataIC50: 273nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Respivert

US Patent
LigandPNGBDBM347671(3-((4-((4-(3-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl...)
Affinity DataIC50: 275nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Respivert

US Patent
LigandPNGBDBM347674(3-Ethynyl-5-((4-((4-(3-(3-(2-methylbut-3-yn-2-yl)-...)
Affinity DataIC50: 296nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Respivert

US Patent
LigandPNGBDBM347675(1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...)
Affinity DataIC50: 348nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Respivert

US Patent
LigandPNGBDBM256621(US9481648, Ref Cpd A | US9790209, Example 2)
Affinity DataIC50: 380nMAssay Description:The inhibitory activities of test compounds against the p38 MAPKα isoform (MAPK14: Invitrogen), are evaluated indirectly by determining the leve...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Respivert

US Patent
LigandPNGBDBM347663(3-Methoxy-5-((4-((4-(3-(3-(2-methylbut-3-yn-2-yl)-...)
Affinity DataIC50: 539nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Respivert

US Patent
LigandPNGBDBM347664(1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...)
Affinity DataIC50: 602nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Respivert

US Patent
LigandPNGBDBM347660(1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...)
Affinity DataIC50: 1.00E+3nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Respivert

US Patent
LigandPNGBDBM347669(1-(4-((2-((6-(2-(Dimethylamino)ethoxy)pyridin-2-yl...)
Affinity DataIC50: 1.76E+3nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Respivert

US Patent
LigandPNGBDBM347667(1-(4-((2-((3-Methoxy-5-(2-morpholinoethoxy)phenyl)...)
Affinity DataIC50: 2.57E+3nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Respivert

US Patent
LigandPNGBDBM256621(US9481648, Ref Cpd A | US9790209, Example 2)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Respivert

US Patent
LigandPNGBDBM347670(1-(4-((2-((4-(2-(Dimethylamino)ethoxy)pyridin-2-yl...)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Respivert

US Patent
LigandPNGBDBM347668(1-(2,3-Dichloro-4-((2-((7-methyl-1H-indazol-5-yl)a...)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Respivert

US Patent
LigandPNGBDBM347660(1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Respivert

US Patent
LigandPNGBDBM347666(1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Respivert

US Patent
LigandPNGBDBM347662(1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Respivert

US Patent
LigandPNGBDBM347675(1-(3-(2-Methylbut-3-yn-2-yl)-1-(p-tolyl)-1H-pyrazo...)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Respivert

US Patent
LigandPNGBDBM347676(1-(4-((2-((6-(2-(2-(2-Methoxyethoxy)ethoxy)ethoxy)...)
Affinity DataIC50: 1.00E+4nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
Go to US Patent